Are Allogeneic CAR-Ts the Future of LBCL Cancer Treatment? – Making Safe, Durable & Effective Universal Cell Therapies a Reality

Allogene Therapeutics recently released exciting results from the Phase 1 ALPHA/ALPHA2 trials of the Allogeneic CAR T 'Cemacabtagene Ansegedleucel/ALLO-501' in Relapsed/Refractory Large B-Cell Lymphoma.

Continue ReadingAre Allogeneic CAR-Ts the Future of LBCL Cancer Treatment? – Making Safe, Durable & Effective Universal Cell Therapies a Reality

Researchers identify molecular glues that protect insulin-producing cells from damage related to diabetes

Researchers have discovered a novel approach to protecting insulin-producing beta cells from the damaging effects of glucolipotoxicity - a harmful condition linked to the progression of type 2 diabetes (T2D).…

Continue ReadingResearchers identify molecular glues that protect insulin-producing cells from damage related to diabetes